“According to Renub Research forecast the global Spinal Muscular Atrophy Market to grow at a CAGR of 14% in the coming years.”

Renub Research report titled “Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)” studies the global spinal muscular atrophy market and provides an all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.

Spinal muscular atrophy (SMA) is one of the most common genomic disorders which are caused due to the loss of specialized nerve cells known as motor neurons in the brainstem and spinal cord. The impairment of motor neurons leads to the weakness and atrophy of muscles used for the regular activities like crawling, sitting, walking and the head movement. In worst cases, the muscles used for breathing and swallowing also get affected. On the basis of severity of muscle weakness, the age of disease commencement, there are four types of spinal muscular atrophy namely type 1, type 2, type 3 and type 4. Type 1, 2 and 3 of spinal muscle atrophy appears in childhood while type 4 appears in adulthood. According to Renub Research forecast the global Spinal Muscular Atrophy Market to grow at a CAGR of 14% in the coming years. This high growth rate is primarily due to good reimbursement options in western countries, declining drug prices and projected launch of new drugs. 

One of the major growth drivers witnessing the growth of spinal muscular atrophy market is growing awareness of diagnosis and treatment of spinal muscular atrophy during the forecast period. The awareness about the spinal muscular atrophy diagnosis and treatment is growing among the patients. The recent outcome of spinal muscular atrophy treatment further plays a significant role in spreading awareness about the disease. 

 

 

Additionally, increasing government and non-government support for the treatment and diagnosis of spinal muscular atrophy further boost the growth Global Spinal Muscular Atrophy Market over the coming years. The government of several countries across the world has developed regulations to help medical professionals and caregivers decide when to administer the cure to the infants with spinal muscular atrophy. For instance: In 2018, the Canadian organization of rare disorders signed a petition for funding SPINRAZA for the treatment of Canadian patients with spinal muscular atrophy. Furthermore, one of the key factors attributing to the growth of the spinal muscular atrophy market is the rising investing by the key market players for the research and development of new and effective spinal muscular atrophy therapies.

 

 

 

Spinal muscular atrophy generally shows its symptoms in early childhood and is a prime cause of mortality in infants. According to Spinal Muscular Atrophy (SMA) Foundation 2015 statistics, spinal muscular atrophy has been affected nearly 10,000 to 25,000 children and adults in the United States. The rising incidence of damaged spinal muscular atrophy gene amongthe infants around the world is expected to boost the growth of spinal muscular atrophy in the next couple of years. On the other hand, the high cost of drugs and treatment is likely to restrain the growth of spinal muscular atrophy market over the forecast period. For example, Biogen’s Spinraza (nusinersen) medicine for spinal muscular atrophy (SMA) is estimated to cost US$ 125,000 per injection, accounting huge expense for the treatment.

 

Client can Purchase this Report in Sections from below link:

 

 

 

Market Summary

1-  Country-wise, the report provides the Spinal muscular atrophy market and market share of United States, United Kingdom, France, Germany, Spain, Italy and Japan.

2-  Number of Patients-wise the report provides the total & treated patients population and population share of United States, United Kingdom, France, Germany, Spain, Italy and Japan.

3-  Drug-wise, the report provides present and estimated global sales of Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070.

4-  Company-wise the report provides present and estimated global of Biogen Inc., Roche AG, Novartis AG and Cytokinetics Inc.

5-  Drugs Clinical Phase Study, The report provides 113 Drugs clinical study pipeline status Which is at present, globally in the various stage such as (Phase I, II and III) unknown status, recruiting, active, not recruiting, terminated or completed stage.

 

If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at info@renub.com  

 

 

Browse Related Report :

 

Contact Us

Renub Research

Phone:+1-678-302-0700

Email: info@renub.com

 

Key Topics Covered :

1. Introduction

    1.1 Market Definition
    1.2 Currency Conversion

2. Research Methodology

3. Executive Summary

4. Global Spinal Muscular Atrophy Market and Patients Analysis

    4.1 Spinal Muscular Atrophy Market
    4.2 Spinal Muscular Atrophy Patient Numbers
    4.3 Spinal Muscular Atrophy Treated Patient Number

5. Share Analysis – Global Spinal Muscular Atrophy

    5.1 Country Market Share
    5.2 Patients Population Share
    5.3 Treated Patients Share

6. United States

    6.1 Spinal Muscular Atrophy Market
    6.2 Spinal Muscular Atrophy Patient Numbers
    6.3 Spinal Muscular Atrophy Treated Patients

7. United Kingdom

    7.1 Spinal Muscular Atrophy Market
    7.2 Spinal Muscular Atrophy Patient Numbers
    7.3 Spinal Muscular Atrophy Treated Patient Numbers

8. Germany

    8.1 Spinal Muscular Atrophy Market
    8.2 Spinal Muscular Atrophy Patient Numbers
    8.3 Spinal Muscular Atrophy Treated Patients

9. Italy – Spinal Muscular Atrophy

    9.1 Spinal Muscular Atrophy Market
    9.2 Spinal Muscular Atrophy Patient Numbers
    9.3 Spinal Muscular Atrophy Treated Patient Numbers

10. France – Spinal Muscular Atrophy

    10.1 Spinal Muscular Atrophy Market
    10.2 Spinal Muscular Atrophy Patient Numbers
    10.3 Spinal Muscular Atrophy Treated Patient Numbers

11. Spain

    11.1 Spinal Muscular Atrophy Market
    11.2 Spinal Muscular Atrophy Patient Numbers
    11.3 Spinal Muscular Atrophy Treated Patient Numbers

12. Japan

    12.1 Spinal Muscular Atrophy Market
    12.2 Spinal Muscular Atrophy Patients
    12.3 Spinal Muscular Atrophy Treated Patient Numbers

13. Drugs Sales – Spinal Muscular Atrophy

    13.1 Spinraza
    13.2 AVXS-101
    13.3 CK2127107
    13.4 RG7916
    13.5 Olesoxime
    13.6 LMI070

14. Spinal Muscular Atrophy Study Status Analysis

    14.1 Spinal Muscular Atrophy Clinical Study
    14.2 Spinal Muscular Atrophy Drugs Development Pipeline

15. Growth Drivers

    15.1 Increasing Funding for Research & Development
    15.2 Biogen Access Programs

16. Challenges

    16.1 High Treatment Cost
    16.2 Common Side Effects

17. Biogen Inc.

    17.1 Business Overview
    17.2 Initiatives/Strategies
    17.3 Financial Insight

18. Novartis AG

    18.1 Business Overview
    18.2 Initiatives/Strategies
    18.3 Financial Insight

19. Roche Holding AG

    19.1 Business Overview
    19.2 Initiatives/Strategies 
    19.3 Financial Insight

20. Cytokinetics, Inc.

    20.1 Business Overview
    20.2 Initiatives/Strategies
    20.3 Financial Insight

 

About Us

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Media Contact
Company Name: Renub Research
Contact Person: Rajat Gupta
Email: Send Email
Phone: +1-678-302-0700
Address:225 Kristie Ln
City: Roswell
State: Georgia
Country: United States
Website: www.renub.com/drugs-and-pharmaceuticals-13-c.php

 

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com